Paul L. Berns President and Chief Executive Officer
Bruce K. Bennett Vice President, Pharmaceutical Operations
David C. Clark Vice President, Finance and Treasurer
Bruce A. Goldsmith Ph.D. Senior Vice President, Corporate Development
Marc H. Graboyes Senior Vice President, General Counsel
Charles Q. Morris MB ChB, MRCP, Executive Vice President, Chief Medical Officer
Michael E. Schick Vice President, Sales and Marketing
Paul L. Berns President and Chief Executive Officer
Mr. Berns has served as the Company’s President and Chief Executive Officer, and as a member of the Board of Directors, since March 2006. Prior to joining the Company, Mr. Berns was a self-employed consultant to the pharmaceutical industry from July 2005 to March 2006. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. Prior to that, from 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories, a pharmaceutical company. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals-Knoll, a pharmaceutical company, and from 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Berns is a director of XenoPort, Inc. Mr. Berns received a B.S. in Economics from the University of Wisconsin.
Bruce K. Bennett Vice President, Pharmaceutical Operations
Mr. Bennett has served as the Company’s Vice President, Pharmaceutical Operations since January 2008. Prior to joining the Company, Mr. Bennett was a self-employed consultant to the biotechnology and pharmaceutical industries from 2006 to January 2008. From 2002 to 2006, Mr. Bennett served as Vice President, Manufacturing at La Jolla Pharmaceuticals. Prior to La Jolla, Mr. Bennett served as Vice President, Operations at Provasis Therapeutics from 2000 to 2002, and as Vice President, Operations, RA/QA/QC and Commercial Development at Via Medical Corporation from 1997 to 2000. From 1987 to 1997, Mr. Bennett served as a senior operations executive of various pharmaceutical, biotechnology and other companies. Mr. Bennett earned his M.B.A. from Pepperdine University and his B.S. in Industrial Technology from California State University, Long Beach.
Back to top
David C. Clark Vice President, Finance and Treasurer
Mr. Clark has served as the Company’s Vice President, Finance since February 2007, as Principal Financial Officer since March 2006 and as the Company’s Treasurer since May 2004. Mr. Clark also served as the Company’s Corporate Controller from May 2004 to April 2007. He has served as the Company’s Assistant Secretary since October 2004 and served as Secretary from May 2004 to October 2004. From March 2000 to October 2003, Mr. Clark held several positions at Seurat Company (formerly XOR Inc.), a technology company, serving most recently as Vice President of Finance and Chief Financial Officer. From 1992 to March 2000, Mr. Clark worked in the audit practice of PricewaterhouseCoopers LLP. Mr. Clark is a Certified Public Accountant and received a Masters of Accountancy and a B.S. in Accounting from the University of Denver.
Bruce A. Goldsmith, Ph.D. Senior Vice President, Corporate Development
Dr. Goldsmith has served as the Company’s Vice President, Corporate Development since July 2008. Prior to joining the Company, Dr. Goldsmith served as Vice President, Strategic Marketing at GPC Biotech, a biotechnology company, from May 2007 to July 2008. Prior to that, from May 1999 to April 2007, Dr. Goldsmith served in various strategic marketing and business development roles with the Johnson & Johnson family of companies, where he served most recently as Group Product Director, Virology for Tibotec Therapeutics from 2005 to 2007 and Executive Director, Global Marketing Leader, Oncology, from 2003 to 2005. From 1994 to 1997, Dr. Goldsmith was a Research Fellow with the Japan Pharmaceutical Group at Novartis Pharma. Dr. Goldsmith earned his M.B.A. from Columbia Business School and his Ph.D. in Neuroscience from the University of Pennsylvania. He received his B.A. in Biology from Colgate University.
Marc H. Graboyes Senior Vice President, General Counsel
Mr. Graboyes has served as the Company’s Senior Vice President, General Counsel and Secretary since February 2008, and served as the Company’s Vice President, General Counsel and Secretary from October 2004 to January 2008. From 2000 to October 2004, Mr. Graboyes was an attorney with Cooley Godward LLP, where he practiced corporate and securities law and served as outside counsel to the Company. Prior to joining Cooley Godward, Mr. Graboyes practiced corporate and securities law with several other national law firms. Mr. Graboyes earned his J.D. from the University of Colorado School of Law and received his B.S. in Entrepreneurship & Small Business Management from the University of Colorado at Boulder.
Charles Q. Morris MB ChB, MRCP, Executive Vice President, Chief Medical Officer
Dr. Morris has served as the Company's Executive Vice President, Chief Medical Officer since April 2010. Prior to joining Allos, Dr. Morris joined Cephalon in July 2007 and most recently served as Vice President, Worldwide Clinical Research focused on oncology, immunology and neuroscience development portfolios. His significant contributions helped Cephalon achieve the first oncology drug approvals for chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma (NHL). Prior to 2007, Dr. Morris spent the majority of his career at AstraZeneca Pharmaceuticals (formerly Zeneca Pharmaceuticals), where he most recently served as Vice President, Clinical Development Projects, Oncology. He held a number of leadership roles during his tenure with AstraZeneca, including leading the clinical aspects of the Company's successful new drug application submission for metastatic breast cancer and prostate cancers, and later providing oversight for the clinical development of all late state pipeline and marketed products. Dr. Morris received Degrees of Bachelor of Medicine and Bachelor of Surgery, Degree of Bachelor of Medical Science in Clinical Pharmacology and Therapeutics from the Sheffield University Medical School, United Kingdom, and is a member of the Royal College of Physicians of London.
Michael E. Schick Vice President, Sales and Marketing
Mr. Schick has served as the Company’s Vice President, Marketing since August 2009. Prior to joining the Company, Mr. Schick served as Associate Vice President, Oncology Marketing at ImClone Systems from October 2007 to July 2009, where he was responsible for the Erbitux® (cetuximab injection) franchise across multiple indications. Prior to that, from February 2006 to October 2007, Mr. Schick was Executive Director, Oncology Global Marketing at Amgen Inc., where he was responsible for marketing Neulasta® (pegfilgrastim) and Aranesp (darbepoetin alfa injection). From November 2004 to January 2006, Mr. Schick served as Director, Marketing, Oncology at Pharmacyclics, Inc. Prior to that, Mr. Schick served in a variety of commercial roles at Bristol Myers Squibb, including sales, strategic planning and product management focused on multiple brands including Taxol® (paclitaxel injection) and Paraplatin® (carboplatin for injection). Mr. Schick earned his B.A. from Villanova University.